Investor Relations
Capital partners for pharma-grade longevity.
Founded in 2022, Nanyang Biologics is building a vertically integrated AI drug discovery platform — from a 2B+ compound library to clinical assets in metabolic health, inflammation, and oncology.
Key metrics
- Compound library
- 2B+
- Natural compounds
- 10M+
- Higher hit rate
- 64x
- Bioactivity prediction efficiency
- 44.83%
Virtually screenable molecules accessible through our AI pipeline.
Plant-derived bioactives indexed for screening.
Improvement over the most popular molecular docking software.
Increase reported in our IEEE DTIGN paper versus baseline.
Company milestones
2022
Founding
Nanyang Biologics is incorporated in Singapore.
2024
DTIGN publication
Drug-Target Interaction Graph Neural Network published on IEEE Xplore.
2025
LigoSpace at NeurIPS 2025
LigoSpace, developed with NTU Singapore, presented at NeurIPS 2025.
2026
NVIDIA GTC 2026
Exhibited at NVIDIA GTC 2026, March 16–19.
Leadership
Roland Ong, PhD
Founder and Chairman
TODO(content): bio.
Winifred Yau, PhD
Chief Executive Officer
TODO(content): bio.
Yi Chieh Lim, PhD
Chief Scientific Officer
TODO(content): bio.
Micheal Fong
Chief Strategy & Planning
TODO(content): bio.
Giang Nguyen
Chief Technology Officer
TODO(content): bio.
Duy Trieu
Director of Engineering
TODO(content): bio.
Quynh Nguyen
Senior AI Partnership Manager
TODO(content): bio.
Minh To
Innovation Manager
TODO(content): bio.
Vinh Nguyen
AI Engineer
TODO(content): bio.
Trang Nguyen
BD Associate
TODO(content): bio.
Press kit
Company fact sheet, leadership headshots, brand assets, and the DTIGN paper.
Investor contact
We'll respond within 2 business days with a data-room access form.
Step 2 of 3